LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

Kodu・Aktsiate loetelu・Biogen Inc

Biogen Inc

Suletud

SektorTervishoid

140.29 0.24

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

140.04

Max

141.94

Põhinäitajad
By Trading Economics
Sissetulek	394M 635M
Müük	215M 2.6B
P/E Sektori keskmine	12.653 35.733
Aktsiakasum	3.02
Kasumimarginaal	23.995
Töötajad	7,605
EBITDA	457M 1B

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+20.72% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	29. okt 2025

Turustatistika
By TradingEconomics
Turukapital	442M 19B
Eelmine avamishind	140.05
Eelmine sulgemishind	140.29

Uudiste sentiment

By Acuity

31%

69%

92 / 371 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bearish Evidence

118.15 / 121.17 Toetus ja vastupanu

Biogen Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

6. sept 2025, 09:30 UTC

Omandamised, ülevõtmised, äriostud

Armani Stuck to the Classics. But His Business Needs a Refresh -- Heard on the Street -- WSJ

6. sept 2025, 08:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

5. sept 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

5. sept 2025, 20:37 UTC

Omandamised, ülevõtmised, äriostud

Blue Water: Assets of Auction Include Nationwide Retail Distribution Network of More Than 4,000 Branded Service Stations >BLUWU

5. sept 2025, 20:37 UTC

Omandamised, ülevõtmised, äriostud

Blue Water: Assets of Auction Include Lubricant and Blending Plants Supporting Specialty Fuels and Lubricants >BLUWU

5. sept 2025, 20:36 UTC

Omandamised, ülevõtmised, äriostud

Blue Water: Assets of Auction Include Midstream Infrastructure, Including Pipelines and Terminals Such as the Sour Lake Crude Pipeline >BLUWU

5. sept 2025, 20:36 UTC

Omandamised, ülevõtmised, äriostud

Blue Water: Assets of Auction Include Refineries at Lake Charles, La., Lemont, Ill., Corpus Christi, Texas, With Combined Refining Capacity Exceeding 800,000 Barrels per Day >BLUWU

5. sept 2025, 20:33 UTC

Omandamised, ülevõtmised, äriostud

Blue Water: Proposal Would Provide $3.2B Settlement for Holders of PDVSA 2020 Bonds to Be Paid Either in Cash or in Shrs of Publicly Listed Entity That Will Own Citgo >BLUWU

5. sept 2025, 20:33 UTC

Omandamised, ülevõtmised, äriostud

Blue Water: Proposal Would Provide Cash or Stk Distributions to PDV Holding Inc.'s General Creditors >BLUWU

5. sept 2025, 20:31 UTC

Omandamised, ülevõtmised, äriostud

Blue Water Acquisition Corp. III: Announces Submission of $10B Bid for PDV Holding Inc., Parent of Citgo Petroleum Corp.

5. sept 2025, 20:20 UTC

Tulu

These Stocks Moved the Most Today: Broadcom, Nvidia, Lululemon, Tesla, Samsara, Kenvue, Guidewire, and More -- Barrons.com

5. sept 2025, 19:23 UTC

Market Talk

Oil Futures Extend Losses Ahead of OPEC+ Meeting -- Market Talk

5. sept 2025, 19:22 UTC

Tulu

Week's Best: Insurance Costs, Like Sea Levels, Are Rising -- Barrons.com

5. sept 2025, 19:17 UTC

Market Talk

U.S. Natural Gas Snaps Winning Streak -- Market Talk

5. sept 2025, 18:59 UTC

Tulu

These Stocks Are Moving the Most Today: Broadcom, Nvidia, Lululemon, Tesla, Samsara, Kenvue, Guidewire, and More -- Barrons.com

5. sept 2025, 18:35 UTC

Market Talk

BMO Leans Toward September Canada Rate Cut After 'Exceptionally Weak' Jobs Report -- Market Talk

5. sept 2025, 17:25 UTC

Market Talk

Bets on Hefty Fed Cut Seen as Exaggerated -- Market Talk

5. sept 2025, 17:20 UTC

Market Talk

U.S. Oil Rig Count Rises By 2 to 414 -- Market Talk

5. sept 2025, 17:17 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5. sept 2025, 17:17 UTC

Market Talk

Bank of Canada Policy Seen Moving to Expansionary Territory -- Market Talk

5. sept 2025, 17:03 UTC

Market Talk

Bank of Canada Expected to Cut, But Inflationary Pressures Remain a Concern -- Market Talk

5. sept 2025, 16:39 UTC

Omandamised, ülevõtmised, äriostud

Yorkville Acquisition: Commencing at Market Open on Sept 8, Common Stk Will Trade on Nasdaq Under New Ticker Symbol 'MCGA' >YORK

5. sept 2025, 16:39 UTC

Omandamised, ülevõtmised, äriostud

Yorkville Acquisition: Will Be Renamed to Trump Media Group CRO Strategy Upon Closing of Combination Between Yorkville, Trump Media & Technology Group Corp. and Crypto.com >YORK

5. sept 2025, 16:39 UTC

Omandamised, ülevõtmised, äriostud

Yorkville Acquisition Corp.: Announces Ticker Symbol Change to 'MCGA' Ahead of Trump Media Group CRO Strategy, Inc. Listing

5. sept 2025, 16:39 UTC

Omandamised, ülevõtmised, äriostud

Yorkville Acquisition: Outstanding Publicly Traded Units and Warrants Will Trade on Nasdaq Under New Ticker Symbols 'MCGAU' and 'MCGAW', Respectively >YORK

5. sept 2025, 16:37 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Global Equities Roundup: Market Talk

5. sept 2025, 16:37 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Global Energy Roundup: Market Talk

5. sept 2025, 16:37 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Strathcona Buys Up More MEG Shares In Effort to Scuttle Cenovus Deal -- Market Talk

5. sept 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

5. sept 2025, 16:16 UTC

Tulu

These Stocks Are Moving the Most Today: Broadcom, Nvidia, Lululemon, Tesla, Samsara, Guidewire, and More -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Biogen Inc Prognoos

Hinnasiht

By TipRanks

20.72% tõus

12 kuu keskmine prognoos

Keskmine 169.81 USD 20.72%

Kõrge 260 USD

Madal 118 USD

Põhineb 26 Wall Streeti analüütiku instrumendi Biogen Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

26 ratings

Osta

Hoia

Müü

Põhineb 26 analüütiku instrumendi Biogen Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

118.15 / 121.17Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

92 / 371 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.